Compound represented by the general formula (I), a salt thereof, a prodrug thereof or a solvate thereof, the present invention is expected to be highly effective than leukotriene receptor antagonists which are used currently in clinical It has a leukotriene receptor antagonism can be, leukotriene mediated diseases, for example, respiratory diseases [for example, (such as interstitial pneumonia) bronchial asthma, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, pneumonia, severe expectorant and prophylactic and / or therapeutic agents (eg, acute sinusitis, and chronic sinusitis) of] such as acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis, it is useful as antitussive. In the formula, the meaning of all symbols as described in the specification. ]本発明は、一般式(I)で示される化合物、その塩、それらの溶媒和物、またはそれらのプロドラッグであり、現在臨床で用いられているロイコトリエン受容体拮抗薬よりも高い有効性が期待できるロイコトリエン受容体拮抗作用を有するので、ロイコトリエン介在性疾患、例えば、呼吸器疾患[例えば、気管支喘息、慢性閉塞性肺疾患、肺気腫、慢性気管支炎、肺炎(例えば、間質性肺炎など)、重症急性呼吸器症候群(SARS)、急性呼吸窮迫症候群(ARDS)、アレルギー性鼻炎、副鼻腔炎(例えば、急性副鼻腔炎、慢性副鼻腔炎など)等]の予防および/または治療薬や去痰薬、鎮咳薬として有用である。[式中、すべての記号の意味は明細書中に記載の通り。]
